Partnership will launch photobiomodulation device to tackle mucositis and dermatitis

Oncology Imaging Systems Limited (OIS) has entered an exclusive partnership agreement with NeoMedLight, a Horizon2020 Small and Medium Enterprise (H2020 SME) award winner that develops innovative medical devices targeted at a better delivery of phototherapy. NeoMedLight was selected from thousands of European candidates, receiving a 2,4M€ grant from the European Commission for its CareMin650 device featuring exclusive technology: a fabric emitting light through woven optic fibres.

CareMin650 is a pioneering solution leveraging NeoMedLight’s unique Lightex technology to tackle the clinical challenges of mucositis and dermatitis – severe and frequent radiotherapy and chemotherapy side effects in cancer patients. These conditions result in lesions which cause considerable pain in the oral mucosa and skin, especially in the case of breast cancer, head and neck cancer, leukaemia as well as gynaecological and prostate cancers. The CareMin650 is a non-invasive solution that offers a quick, simple, and cost-effective way to deliver photobiomodulation therapy to patients within the oncology setting. “I’m really excited about this agreement,” Steve Imber, Managing Director of OIS, explains. “CareMin650 represents a major advance in care and wellbeing for many patients undergoing radiotherapy.”

Speaking about the partnership, Pierre Saint-Girons, Cofounder and CEO of NeoMedLight, said “NeoMedLight is very pleased to have signed an exclusive partnership agreement with OIS to market our CareMin650 system in the UK and Ireland. OIS has a highly qualified and professional team that enjoys an excellent reputation with its customers. We are confident that their in-depth market knowledge and dynamism will make the launch of CareMin650 a success. Together we are providing an innovative, easy to use and effective solution to the problem of mucositis and dermatitis in treating cancer patients.”

This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more